Nuclear Medicine, Molecular Imaging Industry Group Forms

Facebook X LinkedIn Email
The Society of Nuclear Medicine and Molecular Imaging’s (SNMMI’s) Value Initiative Industry Alliance has been established to connect corporate members to the future of nuclear medicine and molecular imaging and relevant stakeholders.

Value Initiative Industry Alliance corporate members aim to help shape the field's future by providing funding support, strategic industry guidance, and collaborative knowledge-sharing. The Industry Alliance is led by an advisory committee, which is co-chaired by James Williams, head of Siemens Healthineers Molecular Imaging, and Jonathan Allis, CEO of Blue Earth Diagnostics. The alliance will help implement SNMMI's Value Initiative, which provides the vision for, and forms the basis of, the society's new strategic plan and focuses on five key domains: quality of practice, R&D, workforce pipeline, advocacy, and outreach.

"SNMMI is proud to work with these industry leaders and their companies, and honored to strengthen that collaboration through the Value Initiative Industry Alliance," said SNMMI vice president Satoshi Minoshima, chair of the Value Initiative Board. "Innovative nuclear medicine and molecular imaging research is beginning to transform precision medicine and patient outcomes. Working together with Alliance participants, which range from small businesses to the largest corporations in the industry, we can advance scientific discoveries and rapidly translate them to patient care with more effective diagnostics and targeted therapy."

"As a manufacturer of both PET scanners and PET radiopharmaceuticals, Siemens Healthineers Molecular Imaging relies on our relationship with the SNMMI to support, expand and develop the role of PET in clinical imaging, and on research efforts like the clinical trials network to expand the future scope of nuclear medicine,” Williams said.

"In the past four years, Blue Earth Diagnostics has partnered closely with the SNMMI on a range of activities supporting the development and commercial introduction of Axumin [fluciclovine F-18], our FDA-approved PET imaging agent, in the U.S.," Allis said. "Of particular value is our partnership with SNMMI on training readers how to optimally interpret Axumin scans. We hope, via the Value Initiative, to allow other companies to benefit from and to contribute to the growth of nuclear medicine."

Alliance work is already underway, and members, including representatives from Blue Earth Diagnostics, Siemens Healthineers Molecular Imaging, Jubilant DraxImage Inc., and Advanced Accelerator Applications, will meet during SNMMI's annual meeting in late June.

Published: June 2018
BusinessSociety of Nuclear Medicine and Molecular ImagingSNMMIValue Initiative Industry AlliancepartnershipsAmericasRapidScan

We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.